Director/PDMR Shareholding

RNS Number : 8811Q

Venture Life Group PLC

03 March 2016

 

Venture Life Group PLC

("Venture Life" or the "Company")

Director/PDMR Shareholding

Bracknell, UK - 3 March 2016: Venture Life Group plc (AIM: VLG), the international consumer healthcare group addressing the self-care needs of the ageing population, announces that it was informed on 2 March 2016 that Mr. Jerry Randall, the Chief Executive Officer of the Company, transferred 115,000 ordinary shares of 0.3p each in the Company ("Ordinary Shares") to his SIPP (the "Transfer"). The Transfer was made by way of a sale at a price of 65.00p per Ordinary Share and purchase at a price of 65.02p per Ordinary Share.  Following the Transfer and pursuant to the announcement made by the Company on 12 February 2016, Mr. Randall's beneficial interest (including associated holdings) in the Company remains unchanged at 3,931,129 Ordinary Shares, representing approximately 10.7% of the issued share capital in the Company.

For further information please contact:

Venture Life Group PLC

Jerry Randall, Chief Executive Officer                                                    [phone]

James Hunter, Chief Financial Officer                                                   

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)                             
Freddy Crossley                                                                                                               [phone]

Peter Steel

Duncan Monteith                                                                                                           
Corporate Finance

Tom Salvesen
Corporate Broking                                                                                                          

Square1 Consulting

David Bick

Brian Alexander                                                                                                               [phone]

About Venture Life

Venture Life is an international consumer self-care company focused on developing, manufacturing and commercialising products for the ageing population. The Group's product range and pipeline currently includes food supplements for lowering cholesterol and maintaining brain function, dermo-cosmetics for addressing the signs of ageing, and medical devices for improving minor aches and pains, dry eyes and itchy skin. The products, which typically are recommended by pharmacists or healthcare practitioners, are available primarily through pharmacies supplied by the Group's international distribution partners.

Venture Life announced on 12 February 2016 a proposed placing and issue of convertible bonds in connection with the proposed acquisition of Periproducts Limited, an oral care products company with a range of premium products including mouthwashes, which are alcohol-free, and toothpastes.

Products in Periproducts' leading range, UltraDEX®, are used to treat bad breath, remineralise and whiten teeth and kill bacteria which cause plaque, which can in turn lead to tooth decay and gum disease. Incorporating patent protected and licensed intellectual property, the UltraDEX® products, including UltraDEX® Recalcifying & Whitening range, are regarded as being particularly effective at managing bad breath, as supported by clinical data evidencing efficacy.  Completion of the acquisition of Periproducts, and the related Placing and issue of convertible bonds, are expected to take place on or around 3 March 2016.

Through its manufacturing company, Biokosmes, the Group also provides development and manufacturing services to companies in the medical devices and cosmetic sectors.

The Group's own branded products are currently sold or partnered in over 40 countries and currently include:

·     food supplements to maintain brain function and memory;

·     dermo-cosmetics for addressing the signs of skin ageing and hair loss, and

·     medical devices for improving conditions such as minor aches and pains, dry eyes and itchy skin.

The Company has a healthy development pipeline including products in areas such as diabetes, cardiovascular health, obesity, cognitive function and skin ageing. Products coming from the pipeline will be expected to have intellectual property protection and be supported by independent clinical evidence of efficacy.

 

END

 

 

RDSLIFEEVEIVIIR